A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 674-679

  Chu, Franklin M ^a   Picus, Joel ^b   Fracasso, Paula M ^b   Dreicer, Robert ^c   Lang, Zhihui ^d   Foster, Brenda ^d  

^a San Bernardino Urological Associates   (United States)

^b USA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CENTOCOR INC   (United States)

Author keywords

Docetaxel; Intetumumab; Monoclonal antibody; Prostate cancer

Indexed keywords

DOCETAXEL; INTETUMUMAB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SERUM SICKNESS; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTEGRIN ALPHAV; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 79959735566     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9388-4     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
2. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261 (Pubitemid 46211563)
3. Rubin MA, Putzi M, Mucci N et al (2000) Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6:1038-1045 (Pubitemid 30159365)
4. Scher HI, Chung LW (1994) Bone metastases: improving the therapeutic index. Semin Oncol 21:630-656 (Pubitemid 24329140)
5. Sternberg CN (2001) Systemic treatment and new developments in advanced prostate cancer. Eur J Cancer 37(Suppl 7):S147-S157
6. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584 (Pubitemid 24308973)
7. Folkman J (1995) Tumor angiogenesis. In: Mendelsohn J, Howley PM, Isreal MA, Liotta LA (eds) The molecular basis of cancer. W. B. Saunders, Philadelphia, pp 206-232
8. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571
9. Brooks PC, Montgomery AM, Rosenfeld M et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
10. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822
11. Bisanz K, Yu J, Edlund M et al (2005) Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12:634-643 (Pubitemid 41350144)
12. Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta (3) in prostate cancer progression. Neoplasia 4:191-194
13. De S, Chen J, Narizhneva NV et al (2003) Molecular pathway for cancer metastasis to bone. J Biol Chem 278:39044-39050 (Pubitemid 37221807)
14. Edlund M, Miyamoto T, Sikes RA et al (2001) Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12:99-107 (Pubitemid 32194899)
15. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC (2000) Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 27:35-42 (Pubitemid 30103294)
16. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999) Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664 (Pubitemid 29160140)
17. Sanofi-Aventis U.S.: Taxotere Prescribing Information. Available at http://products.sanofi-aventis.us/Taxotere/taxotere.html. Revised November 2008.
18. Mullamitha SA, Ton NC, Parker GJ et al (2007) Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128-2135 (Pubitemid 46649882)
19. Shaffer DR, Leversha MA, Danila DC et al (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:2023-2029 (Pubitemid 46649868)
20. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
21. Willett CG, Duda DG, di Tomaso E et al (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27:3020-3026